Stoke Therapeutics Posts Wider Loss In Q2

Stoke Therapeutics, Inc. (STOK) posted a second quarter net loss of $24.7 million, or
$0.63 per share, compared to a loss of $22.0 million, or $0.60 per share, last year. Revenue was $3.23 million, for the quarter. Research and development expenses were $18.4 million, compared to $14.1 million, last year.

"The Stoke team continues to execute and we look forward to our next readout of data from our ongoing clinical studies of STK-001 in children and adolescents with Dravet syndrome," said Edward M. Kaye, CEO of Stoke Therapeutics.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT